Psf3 Inhibitors

The class of chemicals termed Psf3 Inhibitors includes compounds that indirectly affect the Psf3 protein by targeting different aspects of DNA replication and the cell cycle. These chemicals are not inhibitors of Psf3 per se but can impact the biological pathways where Psf3 is a critical component. For instance, DNA polymerase inhibitors like aphidicolin can halt DNA synthesis, thereby indirectly affecting the role of Psf3 in replication initiation. Topoisomerase inhibitors such as camptothecin and etoposide induce DNA strand breaks, which can have consequences for DNA replication machinery including Psf3.

Other indirect inhibitors include antimetabolites like hydroxyurea and gemcitabine, which deplete nucleotide pools or get incorporated into DNA respectively, leading to disruptions in DNA synthesis where Psf3 is involved. Agents that cause DNA damage, such as cisplatin and mitomycin C, can lead to replication fork stalling, which may indirectly affect the function of Psf3 in maintaining fork stability. Additionally, small molecule inhibitors like palbociclib and CHK1 inhibitor MK-8776, which target cell cycle regulators, can lead to a halt in cell cycle progression, affecting the initiation phase of DNA replication where the GINS complex, including Psf3, is active. Furthermore, PARP inhibitors like olaparib create an environment of DNA repair defects and increased replication stress, which can indirectly challenge Psf3 function in maintaining normal replication fork progression. Similarly, ATR inhibition by chemicals such as VE-821 compromises the DNA damage response and replication fork stability, potentially impacting the role of Psf3. Through these various mechanisms, these chemicals can indirectly influence the activity of Psf3 by modifying the environment in which it operates, affecting DNA replication and cell cycle progression where Psf3 is essential.